Here for you, every second

Locations

United Kingdom
Kiniksa Pharmaceuticals
International, plc
Kiniksa Pharmaceuticals (UK), Ltd.
Third Floor
23 Old Bond Street
London, UK
W1S 4PZ
USA Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
Switzerland
Kiniksa Pharmaceuticals, GmbH
Grafenaustrasse 5
6302 Zug, Switzerland
USA California
Kiniksa Pharmaceuticals Corp.
4660 La Jolla Village Drive
Suite 1025
San Diego, CA 92122

Utility

Contact Us

Main navigation

About Us
Medicines & Pipeline
Patients & Advocacy
Investors
For Healthcare Professionals
- Congress Materials
- Manuscript Publications
Join Us

Menu

IR navigation

News & Events
Stock Information
- Stock Quote & Chart
- Historical Price Lookup
Financial Information
Corporate Governance
Investor Resources

Press Releases

Year

All
2025
2024
2023

11/26/24

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
11/12/24

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
10/29/24

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
10/28/24

Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
10/22/24

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
10/01/24

NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
08/28/24

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
07/23/24

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
07/16/24

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
07/09/24

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
06/24/24

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis
06/17/24

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
06/04/24

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
05/07/24

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
04/23/24

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
04/16/24

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
04/02/24

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
02/28/24

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
02/21/24

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
01/04/24

Kiniksa Pharmaceuticals Provides Corporate Update
01/02/24

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Print Page

RSS

Email Alerts

Search

Image

United Kingdom
Kiniksa Pharmaceuticals
International, plc
Kiniksa Pharmaceuticals (UK), Ltd.
Third Floor
23 Old Bond Street
London, UK
W1S 4PZ
USA Headquarters
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA 02421 USA
(781) 431-9100
Switzerland
Kiniksa Pharmaceuticals, GmbH
Grafenaustrasse 5
6302 Zug, Switzerland
USA California
Kiniksa Pharmaceuticals Corp.
4660 La Jolla Village Drive
Suite 1025
San Diego, CA 92122

Copyright © 2025 Kiniksa Pharmaceuticals
All Rights Reserved. All trademarks mentioned are the property of their respective owners.
Terms of Use | Privacy Policy | Accessibility Statement
|Cookie Policy | Cookie Settings